Kavalactones: Beyond the Basics
Kavalactones are a family of lipophilic lactone compounds found exclusively in the rootstock of the kava plant (Piper methysticum), a large shrub cultivated throughout the Pacific Islands for over 3,000 years. While our introductory article on kavalactones covers the fundamentals, this guide provides a deeper examination of the pharmacological mechanisms, clinical evidence, and safety considerations surrounding these compounds.
Eighteen kavalactones have been identified, but six account for roughly 96% of the pharmacologically active content: kavain, dihydrokavain, methysticin, dihydromethysticin, yangonin, and desmethoxyyangonin. Each has a distinct molecular structure and receptor interaction profile, and the relative proportions of these six compounds define a cultivar’s “chemotype”—the chemical fingerprint that determines its characteristic effects.
Individual Kavalactone Pharmacology
| Kavalactone | Primary Mechanisms | Character |
|---|---|---|
| Kavain (K) | GABA-A potentiation, Na+ channel blockade, norepinephrine reuptake inhibition | Anxiolytic, mentally clear; dominant in “heady” varieties |
| Dihydrokavain (DHK) | GABA-A modulation, muscle relaxation, analgesic activity | Relaxing, mildly sedative; contributes to body calm |
| Methysticin (M) | MAO-B inhibition, Na+ channel effects, glutamate modulation | Neuroprotective potential; affects mood and cognition |
| Dihydromethysticin (DHM) | Strong GABA-A potentiation, deep sedation, muscle relaxation | Heavily sedating; dominant in “heavy” varieties |
| Yangonin (Y) | CB1 cannabinoid receptor affinity, GABA-A modulation | Unique endocannabinoid interaction; mild euphoria |
| Desmethoxyyangonin (DMY) | MAO-B inhibition, dopamine modulation | Mood-elevating, motivating; contributes to “heady” effects |
Mechanisms of Action in Detail
GABA-A Receptor Potentiation
The primary anxiolytic mechanism of kavalactones involves potentiation of GABA-A receptors—the same receptor family targeted by benzodiazepines and barbiturates. However, kavalactones bind to a different site on the GABA-A receptor complex than benzodiazepines. This distinct binding site produces anxiolytic and muscle-relaxant effects while apparently conferring a lower risk of physical dependence and respiratory depression compared to benzodiazepines.
Electrophysiology studies show that kavain and dihydromethysticin are the most potent GABA-A modulators among the six major kavalactones. They increase the frequency and duration of chloride channel opening in response to GABA, enhancing inhibitory neurotransmission without directly activating the receptor in the absence of GABA—an important safety distinction.
Voltage-Gated Sodium Channel Blockade
Kavain and methysticin block voltage-gated sodium channels in a use-dependent manner, similar to local anesthetics like lidocaine. This mechanism contributes to the analgesic and muscle-relaxant properties of kava, and it explains the characteristic numbing sensation experienced when kava is held in the mouth. Sodium channel blockade also modulates neuronal excitability independently of the GABAergic system.
Monoamine Oxidase Inhibition
Methysticin and desmethoxyyangonin demonstrate reversible MAO-B inhibition. MAO-B is the enzyme primarily responsible for degrading dopamine in the brain. By inhibiting this enzyme, these kavalactones may increase dopamine availability, contributing to the mood-elevating and mildly euphoric qualities of kava. Unlike irreversible MAO inhibitors used pharmaceutically, the reversible nature of this inhibition carries a substantially lower risk of hypertensive crisis.
Cannabinoid Receptor Interaction
Yangonin is the only kavalactone with documented affinity for CB1 cannabinoid receptors. This interaction adds a unique pharmacological dimension to kava preparations rich in yangonin. The CB1 receptor is part of the endocannabinoid system involved in mood regulation, appetite, pain perception, and stress response. The functional significance of yangonin’s CB1 affinity at the concentrations achieved through kava consumption is still being investigated.
Multi-Target Synergy
What makes kavalactones pharmacologically remarkable is their simultaneous modulation of multiple neurotransmitter systems—GABA, glutamate, dopamine, norepinephrine, and endocannabinoids—through a single class of structurally related compounds. This multi-target profile may explain why kava produces anxiolysis without the cognitive impairment, dependence risk, or rebound anxiety typically associated with drugs acting on a single target.
Clinical Evidence for Anxiety
Kavalactones have been evaluated in multiple randomized controlled trials for anxiety disorders, providing a stronger clinical evidence base than most botanical anxiolytics.
- Cochrane Review (Pittler & Ernst, 2003): Meta-analysis of 11 RCTs concluded that kava extract was superior to placebo for treating anxiety, with a weighted mean difference of 3.9 points on the Hamilton Anxiety Scale
- Sarris et al. (2013): A 6-week RCT in 75 participants with generalized anxiety disorder found significant reduction in anxiety with a water-soluble kava extract (120 mg kavalactones/day) compared to placebo, with no significant adverse effects on liver function
- Geier & Konstantinowicz (2004): 101 outpatients with anxiety received 200 mg kavain daily for 4 weeks, showing significant anxiety reduction without tolerance development
- Comparison studies: Several trials comparing kava preparations to benzodiazepines (oxazepam) found comparable anxiolytic efficacy with fewer cognitive side effects and no development of dependence
The Hepatotoxicity Question
In the early 2000s, reports of liver damage associated with kava products led to regulatory restrictions in several European countries. Subsequent investigation revealed several important nuances.
- Noble vs. non-noble varieties: Many implicated products used non-noble (“tudei”) kava cultivars or aerial plant parts (stems, leaves) not traditionally consumed, which contain flavokavains with hepatotoxic potential
- Extraction solvent: Acetone and ethanol extracts concentrate different compound profiles than traditional water extraction. Some hepatotoxic cases involved acetone-extracted products
- Pre-existing conditions: Many reported cases involved individuals with pre-existing liver conditions, heavy alcohol use, or concurrent hepatotoxic medications
- Epidemiological evidence: Pacific Island populations consuming large amounts of traditionally prepared kava show no elevated rates of liver disease, suggesting the traditional preparation method is safer than some commercial extraction methods
Safe Kava Selection
To minimize any hepatotoxicity risk: use only products made from noble kava cultivars, prefer water-based or CO2 extractions over acetone extractions, avoid combining with alcohol or hepatotoxic medications, and choose products from vendors providing third-party lab testing with chemotype data. Individuals with liver conditions should consult a physician before use.
Extraction and Preparation
Traditional Water Extraction
Pacific Island preparation involves grinding the kava rootstock, kneading it in water, and straining through a cloth. This cold-water method extracts kavalactones efficiently (water acts as a carrier for the lactone compounds) while leaving behind many non-lactone compounds. This remains the gold standard for safety.
CO2 Supercritical Extraction
Modern supercritical CO2 extraction produces a concentrated kavalactone extract with precise control over the compound profile. This method avoids organic solvents entirely and can achieve standardized kavalactone content suitable for capsule or tablet formulation.
Ethanol Extraction
Alcohol-based tinctures extract a broad spectrum of kava compounds. While effective for kavalactone recovery, ethanol also extracts flavokavains more efficiently than water, which is relevant to the safety considerations discussed above.
Quality and Chemotype Selection
The chemotype—a six-digit number indicating the rank order of the six major kavalactones by concentration—is the most important quality indicator for kava products.
| Chemotype Pattern | Character | Best For |
|---|---|---|
| 42xxxx | Heady, uplifting | Daytime use, social settings |
| 25xxxx | Balanced | General relaxation |
| 52xxxx | Heavy, sedating | Evening use, sleep support |
| 46xxxx | Heady with euphoria | Mood support, social anxiety |
References
- Pittler, M.H. & Ernst, E. “Kava extract versus placebo for treating anxiety.” Cochrane Database of Systematic Reviews, 2003.
- Sarris, J. et al. “Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study.” Journal of Clinical Psychopharmacology, 2013.
- Teschke, R. et al. “Kava hepatotoxicity: a clinical review.” Annals of Hepatology, 2010.
- Cairney, S. et al. “Saccade and cognitive function in chronic kava users.” Neuropsychopharmacology, 2003.
- Ligresti, A. et al. “Kavalactone yangonin: a novel CB1 receptor ligand.” Pharmacological Research, 2012.
- Gleitz, J. et al. “Anticonvulsive action of kavain estimated from its properties on stimulated synaptosomes.” European Journal of Pharmacology, 1996.
- Uebelhack, R. et al. “Inhibition of platelet MAO-B by kava pyrone-enriched extract.” Pharmacopsychiatry, 1998.